Catherine Kubrak

Catherine Kubrak

Auto-generated profile, based on publicly available information

Catherine Kubrak

Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2009 in Head & Neck
Verified
Journal Article
Closed access
PDF file
CKCatherine Kubrak
Catherine Kubrak
KOKärin Olson
Kärin Olson
NJNaresh Jha
Naresh Jha
LJLouise Jensen
Louise Jensen
LMLinda McCargar
Linda McCargar
Vickie Elaine BaracosVickie Elaine Baracos
Vickie Elaine Baracos

1 August 2007 in International Journal of Nursing Studies
Verified
Journal Article
Closed access
CKCathy Kubrak
Cathy Kubrak
LJLouise Jensen
Louise Jensen

22 June 2012 in Head & Neck
Verified
Journal Article
Closed access
PDF file
CKCatherine Kubrak
Catherine Kubrak
KOKärin Olson
Kärin Olson
NJNaresh Jha
Naresh Jha
RSRufus Scrimger
Rufus Scrimger
MPMatthew Parliament
Matthew Parliament
Vickie Elaine BaracosVickie Elaine Baracos
Vickie Elaine Baracos

14 July 2013 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
CKCatherine Kubrak
Catherine Kubrak
KOKärin Olson
Kärin Olson
Vickie Elaine BaracosVickie Elaine Baracos
Vickie Elaine Baracos

1 September 2007 in Cancer Nursing
Verified
Journal Article
Closed access
CKCatherine Kubrak
Catherine Kubrak
LJLouise Jensen
Louise Jensen
Malnutrition ranges from 20% to 80% in oncology patients. Malnutrition has been associated with reduced response to treatment, survival, and quality of life. Therefore, screening for malnutrition in patients with cancer is recommended by clinical practice groups including the Oncology Nursing Society. Nurses are in an ideal position to carry out nutrition screening. Three nutrition screening tools that have been recommended for use with oncology patients by the Oncology Nursing Society are critically evaluated. The Patient Generated-Subjective Global Assessment has demonstrated diagnostic value in oncology patients at risk of malnutrition or who are malnourished.

22 February 2024 in Clinical Nutrition
Verified
Journal Article
Open access
CKCatherine Kubrak
Catherine Kubrak
LMLisa Martin
Lisa Martin
AGAaron J Grossberg
Aaron J Grossberg
BOBrennan Olson
Brennan Olson
FOFaith Ottery
Faith Ottery
Vickie Elaine BaracosVickie Elaine Baracos
Vickie Elaine Baracos
Existing skeletal muscle index (SMI) thresholds for sarcopenia are inconsistent, and do not reflect severity of depletion. In this study we aimed to define criterion values for moderate and severe skeletal muscle depletion based on the risk of mortality in a population of patients with head and neck cancer (HNC). Additionally, we aimed to identify clinical and demographic predictors of skeletal muscle depletion, evaluate the survival impact of skeletal muscle depletion in patients with minimal nutritional risk or good performance status, and finally, benchmarking SMI values of patients with HNC against healthy young adults. Population cohort of 1231 consecutive patients and external validation cohorts with HNC had lumbar SMI measured by cross-sectional imaging. Optimal stratification determined sex-specific thresholds for 2-levels of SMI depletion (Class I and II) based on overall survival (OS). Adjusted multivariable regression analyses (tumor site, stage, performance status, age, sex, dietary intake, weight loss) determined relationships between 2-levels of SMI depletion and OS. Mean SMI (cm2/m2) was 51.7 ± 9.9 (males) and 39.8 ± 7.1 (females). The overall and sex-specific population demonstrated an increased risk of mortality associated with decreasing SMI. Sex-specific SMI (cm2/m2) depletion thresholds for 2-levels of muscle depletion determined by optimal stratification for males and females, respectively (male: 45.2-37.5, and <37.5; female: 40.9-34.2, and <34.2). In the overall population, Normal SMI, Class I and II SMI depletion occurred in 65.0%, 24.0%, and 11.0%, respectively. Median OS was: Normal SMI (114 months, 95% CI, 97.1-130.8); Class I SMI Depletion (42 months, 95% CI, 28.5-55.4), and Class II SMI Depletion (15 months, 95% CI, 9.8-20.1). Adjusted multivariable analysis compared with Normal SMI (reference), Class I SMI Depletion (HR, 1.49; 95% CI, 1.18-1.88; P < .001), Class II SMI Depletion (HR, 1.91; 95% CI, 1.42-2.58; P < .001). Moderate and severe SMI depletion demonstrate discrimination in OS in patients with HNC. Moderate and severe SMI depletion is prevalent in patients with minimal nutrition risk and good performance status. Benchmarking SMI values against healthy young adults exemplifies the magnitude of SMI depletion in patients with HNC and may be a useful method in standardizing SMI assessment.